title: Precocious puberty and body composition: effects of GnRH analog treatment.
abstract: Body composition changes with age and sex differences become significant only after puberty. Boys and girls before the age of 8 yr do not differ in fat, lean or bone mineral mass. Hormonal influences during pubertal development determine the physiological adult male and female body composition phenotype.
  
  
  
  The aim of our study was to evaluate body composition changes due to central precocious puberty (PP) and the specific effects of therapy on these modifications.
  
  
  
  Sixteen patients (14 girls, 2 boys) were included in the study. They were diagnosed as affected by idiopathic PP according to standard hormonal and clinical criteria; anatomic alterations of hypothalamus-hypophysis region were excluded by MRI. Mean age at diagnosis was 5.9 +/- 1.9 yr. All patients received GnRH analog (Leuprolide or Triptorelin) treatment subcutaneously every 4 weeks for at least 1 yr. Mean period of treatment was 3.4 +/- 1.9 yr. Standard anthropometry and body composition analysis were performed at baseline and every 6-12 months. A group of healthy subjects with normal timing of puberty was matched (for age or for pubertal stage) served as the control group (CA or CP, respectively).
  
  
  
  Patients with PP showed at baseline a significant increase of BMI and relative body weight; lean and fat compartments were also increased but not significantly. During treatment, the PP group showed increased fat mass compared to CA (p<0.05), while no difference was found between PP and CP. Lean mass was similar to CA but lower than in CP (p<0.05). During treatment a significant increase in lean mass (both as total as well as limb mass) was observed. After stopping treatment there was no difference between PP and CP, except for lower lean mass (p<0.04).
  
  
  
  When puberty occurs precociously, lean and fat mass are not significantly different from age-matched control subjects. Data collected during treatment confirm a shortening of prepubertal lean mass development and the block of further lean mass development due to puberty itself, while fat mass accumulation continues. The net result of these modifications determines a typical body composition pattern in PP patients, after the end of therapy: lean mass is reduced by a shortening of the prepubertal growing period and by the "menopausal effect" of treatment itself. Fat mass is increased as a consequence of therapy and could lead to future obesity.
authors.affiliation: Pediatric Department, Scientific Institute H San Raffaele, University of Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Chiumello
authors.forename: P
authors.initials: P
authors.lastname: Brambilla
authors.forename: M P
authors.initials: MP
authors.lastname: Guarneri
authors.forename: G
authors.initials: G
authors.lastname: Russo
authors.forename: P
authors.initials: P
authors.lastname: Manzoni
authors.forename: P
authors.initials: P
authors.lastname: Sgaramella
mesh_terms: D000273:Adipose Tissue / Q000473:pathology; D000886:Anthropometry; D001823:Body Composition; D015992:Body Mass Index; D001835:Body Weight; D001927:Brain Diseases / Q000150:complications*; D002675:Child, Preschool; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide